{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT04179760",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "Phase I (Multicenter, Randomized, Open-label, Parallel arm Design) Twenty subjects with moderate to severe Atopic Dermatitis(AD) are planned to be enrolled from 6 sites in Korea and administered with SCM-AGH by intravenous (IV) infusion 3 times at two-week intervals and evaluated for safety during the safety evaluation period (12 weeks after first infusion).\n\nPhase II (Multicenter, Double-blind, Placebo-controlled, Parallel arm) Phase II of the study is randomized, double-blind, placebo-controlled, parallel arm comparison study in adult subjects with moderate to severe AD. 72 subjects with moderate to severe AD are planned to be enrolled from 6 sites in Korea. Following up to a 4-week Screening period, subjects will be randomly assigned to one of the following treatment arms: SCM-AGH or placebo in the ratio of 1:1."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects who are males or females aged >= 19 years\n\nSubjects who are diagnosed with Atopic Dermatitis (AD) based on the Eichenfield revised criteria of Hannifin and Rajka that\n\nhas been present for at least 1 year before the Screening visit, and\nhave chronic AD symptoms continually for at least 6 months before Screening visit\nSubjects who have moderate to severe AD (EASI \u226516) at the Screening visit and Baseline visit\nSubjects who have IGA score \u22653 at the Screening and Baseline visits\nSubjects who have at least 10% of total body surface area affected by AD at the Screening and Baseline visits\nSubjects who can give written informed consent\nSubjects must have applied a stable dose of a bland emollient to affected areas for at least 7 days before the Baseline visit and be willing to continue for the duration of the study\nMale subjects must abstain from heterosexual activities or agree to use a condom through 30 days after the final dose of study drug. Women of childbearing potential (WOCBP) must abstain from heterosexual activities or agree to use effective contraception through 30 days after the final dose of study drug.\n\nEffective contraception for males and/or WOCBP includes:\n\nBlockage methods - spermicides and condoms/spermicides and vaginal diaphragm for contraception, vaginal sponges or cervical cap (where available)\nOral contraceptives (\"the pill\") for at least 1 month\nDepot or injectable birth control or implantable contraception (e.g., Implanon)\nIntrauterine device (IUD)\nDocumented evidence of surgical sterilization at least 6 months prior to Screening visit i.e., tubal ligation or hysterectomy for women or vasectomy for men\nWomen who are post-menopausal, as documented by measurement of follicle stimulating hormone\n\nExclusion Criteria:\n\nSystemic infection or local infection requiring prohibited medications at Screening visit\n\nSubjects who underwent the following treatments within 4 weeks prior to Baseline visit or are scheduled to receive the following treatments within 4 weeks from Baseline at the discretion of investigator:\n\nUse of immunosuppressive/ immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-\u03b3 (interferon-gamma), Janus kinase inhibitors, azathioprine, methotrexate)\nPhototherapy for AD\nAny other systemic therapy used to treat AD or symptoms of AD (approved or off-label use)\nUse of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within at least 2 weeks prior to Baseline\nHistory of anaphylaxis to any biologic therapy or vaccine\nHistory of Guillain-Barr\u00e9 syndrome\nReceipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained\nAny allergen immunotherapy within 4 months prior to or throughout the study\nA value outside the specified range of 90 mmHg - 140 mmHg for systolic blood pressure and 50 mmHg -90 mmHg for diastolic blood pressure (both inclusive) at Screening (can be repeated once at Screening as per Principal Investigator's [PI's] discretion).\nReceipt of live vaccines within 12 weeks prior to Baseline\n\nReceipt of the following biologics:\n\nCell depleting agents such as rituximab: within 6 months prior to Baseline or within time to return of lymphocyte count to normal, whichever is longer\nOther biologics: within 5 half-lives or within 16 weeks prior to Baseline, whichever is longer\nActive infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus (HCV)\nFemale subjects who are pregnant or lactating or female subjects of childbearing potential who have a pregnancy plan or do not agree to use acceptable methods of contraception, excluding females who are in post-menopausal or surgically infertile (bilateral tubal ligation, bilateral oophorectomy or complete hysterectomy)\nReceipt of any investigational drugs within 8 weeks prior to baseline, within 5 half lives of investigational drug or participated in any clinical trials of medical device\nDiagnosed with either primary or recurrent malignancy within 5 years from Screening\nLiver malfunctions with aspartate aminotransferase (AST) / alanine aminotransferase (ALT) level >2x upper limit of normal (ULN) at Screening\nRenal malfunctions with creatinine level >2x ULN at Screening\nQTc (corrected QT interval) prolongation >470 msec or other significant ECG abnormality noted within 14 days of treatment\nHistory of hypersensitivity to antibiotics and antimicrobial agents\nHistory of significant Adverse Events (AEs) during stem cell therapies\nAllergic or hypersensitivity reaction to the IP (Investigational Product), drug of similar class or ingredients [bovine serum, dimethyl sulfoxide (DMSO)]\nFailure to comply with emollient application instructions prior to baseline, per diary\nSubjects who, in the opinion of the investigator, have other unstable intercurrent diseases that confound safety and efficacy assessment\nPlanned or anticipated major surgical procedure during the subject's participation in this study\nSubjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures"
                        ],
                        "EnrollmentCount": [
                              "92"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04179760"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [
                              "Prospective"
                        ],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "Subjects who meet all eligibility criteria for Long Term Follow Up(LTFU) study participation at the ADT2002 End of Treatment(EOT) visit may continue LTFU for a maximum period of up to 240 weeks post first dose of investigational product. No additional dosing will be administered on this LTFU protocol."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects who provide written informed consent\nSubjects who have received at least 1 dose of SCM-AGH in the ADT2002 study\nSubjects who are willing to comply with the visit schedule and study requirements for reporting relevant information to the site.\n\nExclusion Criteria:\n\n1. Subjects who are unable to comply with the visit schedule prior to Week 240 after first dose of SCM AGH"
                        ],
                        "EnrollmentCount": [
                              "92"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04185584"
                        ]
                  }
            ]
      }
}